Mumbai-based company plans to develop and commercialise treatments based on the Alluminox platform in India
Rakuten Medical (Rakuten Medical) has newly established its subsidiary in India, Rakuten Medical India to strengthen its position in the country and expand its presence worldwide. The Mumbai-based company plans to develop and commercialise treatments based on the Alluminox platform in India, beginning with head and neck cancer.
Rakuten Medical’s proprietary technology platform Alluminox combines the power of light with drugs, devices, and other related components to develop new, innovative therapies. Illuminating the targeted cells with non-thermal light activates the cell-bound drug, which leads to rapid and selective cell killing. This therapy has the potential to be the 5th pillar of cancer treatment.
“I am pleased to have established our base in India and to be able to exchange views with prominent Indian medical professionals. By transforming treatment in India where there is a significant number of cancer patients and high unmet needs in the world, we hope to contribute to the lives of as many patients as possible,” said Mickey Mikitani, Co-CEO, Rakuten Medical.
“Rakuten Medical’s technology has an unprecedented mechanism of action that selectively and precisely attacks targeted cells,” said Dr Rajendra Achyut Badwe, Director and Head of Surgical Oncology at Tata Memorial Centre. “We are delighted that Rakuten Medical is bringing its completely new cancer treatment to India. We will collect robust data to ascertain efficacy as well as the effectiveness of this novel therapy in head and neck cancers.”
Dr Devi Prasad Shetty, Founder and Chairman, Narayana Health said, “We are welcoming the pioneering technology of Rakuten Medical, which will potentially help people in India lead healthier lives, and happy to support Rakuten Medical in its mission to ‘Conquer cancer’.”
